ArticleCrohn's & colitis 3602025

Barriers, Drivers, and Outcomes in Transitioning Patients With Inflammatory Bowel Disease From Intravenous to Subcutaneous Infliximab.

John R Campion et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.